Global Retirement Partners LLC Purchases Shares of 5,407 DexCom, Inc. $DXCM

Global Retirement Partners LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 5,407 shares of the medical device company’s stock, valued at approximately $472,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Nuveen LLC purchased a new stake in DexCom in the first quarter valued at approximately $554,893,000. Massachusetts Financial Services Co. MA boosted its holdings in shares of DexCom by 106.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after acquiring an additional 3,410,858 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after acquiring an additional 1,868,241 shares during the period. DSM Capital Partners LLC raised its holdings in shares of DexCom by 252.1% during the second quarter. DSM Capital Partners LLC now owns 1,435,296 shares of the medical device company’s stock worth $125,287,000 after purchasing an additional 1,027,633 shares during the last quarter. Finally, Jennison Associates LLC lifted its position in DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after purchasing an additional 994,300 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Up 1.5%

Shares of DXCM opened at $63.46 on Friday. The firm has a market cap of $24.75 billion, a P/E ratio of 44.07, a PEG ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The stock’s 50 day moving average is $64.31 and its two-hundred day moving average is $75.83. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the prior year, the company posted $0.45 EPS. The business’s quarterly revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach purchased 18,200 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were purchased at an average cost of $55.04 per share, with a total value of $1,001,728.00. Following the purchase, the chief operating officer owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This represents a 5.81% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Richard Alexander Collins sold 3,948 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $55.17, for a total value of $217,811.16. Following the sale, the director owned 37,994 shares of the company’s stock, valued at approximately $2,096,128.98. This trade represents a 9.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 9,999 shares of company stock valued at $619,391. Insiders own 0.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Royal Bank Of Canada cut their price target on DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Robert W. Baird set a $82.00 target price on DexCom in a report on Friday, October 31st. Truist Financial reissued a “buy” rating and issued a $82.00 price target (down from $94.00) on shares of DexCom in a report on Monday, November 3rd. Wells Fargo & Company set a $93.00 price objective on DexCom and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, TD Cowen cut their target price on shares of DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $86.73.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.